Evidence map›Paper›PMID 33940158›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2021

Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo.

Katrina Albert, Diana P Raymundo, Anne Panhelainen, Ave Eesmaa, Liana Shvachiy, Gabriela R Araújo, Piotr Chmielarz, Xu Yan, Aastha Singh, Yraima Cordeiro and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Therapeutic Mechanisms of Exercise in Parkinson's Disease.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 7 countries.

Katrina AlbertInstitute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
Diana P RaymundoInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, 37073 Göttingen, Germany; Protein Advanced Biochemistry, CENABIO, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil.
Anne PanhelainenInstitute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Ave EesmaaInstitute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
Liana ShvachiyDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, 37073 Göttingen, Germany; Centro Cardiovascular da Universidade de Lisboa, Faculdade de Medicina, Universidade de Lisboa, Av Prof Egas Moniz, 1649-028 Lisbon, Portugal.
Gabriela R AraújoInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil; Protein Advanced Biochemistry, CENABIO, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil.
Piotr ChmielarzInstitute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Department of Brain Biochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow 31-343, Poland.
Xu YanNeuroscience Center, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
Aastha SinghInstitute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
Yraima CordeiroFaculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil.
Fernando L PalhanoInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil.
Debora FoguelInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil.
Kelvin C LukCenter for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA.
Andrii DomanskyiInstitute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
Merja H VoutilainenInstitute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Henri J HuttunenNeuroscience Center, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Herantis Pharma Plc, 20520 Espoo, Finland.
Tiago F OuteiroDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, 37073 Göttingen, Germany; Max Planck Institute for Experimental Medicine, 37075 Göttingen, Germany; Institute of Neuroscience, The Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Mart SaarmaInstitute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
Marcius S AlmeidaInstituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil; Protein Advanced Biochemistry, CENABIO, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil. Electronic address: msalmeida@cenabio.ufrj.br.
Mikko AiravaaraInstitute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Neuroscience Center, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. Electronic address: mikko.airavaara@helsinki.fi.
University of Helsinki · FIUniversidade Federal do Rio de Janeiro · BRUniversitätsmedizin Göttingen · DEUniversity of Lisbon · PTUniversity of Pennsylvania · US

Funding

Project IV "Tackling Heterogeneity of Cognitive Trajectory in LBD"U19AG062418 · NIA · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2019 to 2023
$18.1M
Propagation of Lewy pathology in Parkinsons diseaseR01NS088322 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI LUK, KELVIN C · 2015 to 2025
$4.0M
NIA NIH HHS U19 AG062418NINDS NIH HHS R01 NS088322
6 · The paper itself

Abstract

A molecular hallmark in Parkinson's disease (PD) pathogenesis are α-synuclein aggregates. Cerebral dopamine neurotrophic factor (CDNF) is an atypical growth factor that is mostly resident in the endoplasmic reticulum but exerts its effects both intracellularly and extracellularly. One of the beneficial effects of CDNF can be protecting neurons from the toxic effects of α-synuclein. Here, we investigated the effects of CDNF on α-synuclein aggregation in vitro and in vivo. We found that CDNF directly interacts with α-synuclein with a K

Indexed as

alpha-SynucleinAnimalsBinding SitesCell LineDisease Models, AnimalDopamineHumansMagnetic Resonance SpectroscopyMaleMiceModels, MolecularNerve Growth FactorsParkinson DiseasePhosphorylationPrimary Cell CultureProtein Aggregatesalpha-SynucleinCDNF protein, humanDopamineNerve Growth FactorsProtein AggregatesSNCA protein, humanCDNFcerebral dopamine neurotrophic factorMANFmesencephalic astrocyte-derived neurotrophic factorParkinson’s diseasepre-formed α-synuclein fibrilsprotein aggregationsynucleinopathyα-synuclein

Identifiers

PMID33940158
PMCPMC8417450
OpenAlexW3158654074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.